Spherix is a biotechnology company seeking to develop small-molecule anti-cancer therapeutics. Co. owns the rights to patented technology from universities and researchers and it is in the process of developing therapeutic drugs through partnerships with educational institutions. Co.'s pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Co.'s AML and ALL compounds are targeted therapeutics designed to overcome various resistance mechanisms observed with the existing standard of care. DHA-dFdC, Co.'s pancreatic drug, is a compound poised to become the chemotherapy treatment for pancreatic cancer. The AIKI stock yearly return is shown above.
The yearly return on the AIKI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AIKI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|